Camzyos — Blue Cross Blue Shield of Oklahoma

Initial criteria

• 1. ONE of the following: A. The prescriber states the patient has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed OR B. The patient has a diagnosis of symptomatic NYHA class II-III obstructive HCM AND ALL of the following: 1. Patient has left ventricular ejection fraction (LVEF) ≥ 55% AND 2. Left ventricular outflow tract (LVOT) peak gradient ≥ 50 mmHg at rest or with provocation (Valsalva or post-exercise) AND 3. No known infiltrative or storage disorder causing cardiac hypertrophy that mimics obstructive HCM (e.g., Fabry disease, amyloidosis, Noonan syndrome with left ventricular hypertrophy) AND 4. ONE of the following: A. Tried and inadequate response to a beta blocker OR B. Intolerance or hypersensitivity to beta blockers OR C. FDA labeled contraindication to all beta blockers AND 5. ONE of the following: A. Tried and inadequate response to a calcium channel blocker OR B. Intolerance or hypersensitivity to calcium channel blockers OR C. FDA labeled contraindication to all calcium channel blockers OR C. The patient has another FDA labeled indication for the requested agent and route of administration
• 2. ONE of the following: A. Patient’s age is within FDA labeling for the indication OR B. There is support for using the requested agent for the patient's age for the requested indication
• 3. Prescriber is a specialist in the area of the diagnosis (e.g., cardiologist) or has consulted with one
• 4. The patient does not have any FDA labeled contraindications to the requested agent

Reauthorization criteria

• 1. The patient has been previously approved for the requested agent through the plan’s Prior Authorization process
• 2. The patient has had clinical benefit with the requested agent
• 3. Patient has left ventricular ejection fraction (LVEF) ≥ 50%
• 4. Prescriber is a specialist in the area of the patient’s diagnosis (e.g., cardiologist), or has consulted with a specialist
• 5. The patient does not have any FDA labeled contraindications to the requested agent

Approval duration

12 months